GenSight Biologics Confirms Definitive Full-Year 2025 Consolidated Financial Results Are in Line with Estimates

Paris, France, April 3, 2026, 5:00 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today confirmed that its definitive annual results for the fiscal year ended 2025 are in line with the estimated figures published on March 27, 2026.

Confirmation of Results

The definitive consolidated and individual accounts, which were approved by the Board of Directors today, confirm the following key financial indicators as they had been previously estimated:

Annual Consolidated Financial Statements (IFRS)

 Information availability

The audit procedures on the consolidated and individual financial statements are in progress. The statutory auditors’ reports will be issued once the procedures required for the filing of the Universal Registration Document with the Autorité des Marchés Financiers (AMF)[1]. have been completed.

 Going concern

These consolidated financial statements have been prepared on a going concern basis. As such, no adjustments have been made to the financial statements relating to the recoverability and classification of the asset carrying amounts or classification of liabilities that might be necessary should the Company not be able to continue as a going concern.

Financial Position and Recent Funding

As of March 31, 2026, the Company’s available consolidated cash and cash equivalents amounted to €3.2 million (compared to €2.4 million As of December 31, 2025, €2.5 million on December 31, 2024)

In 2025 and early 2026, the Company completed several equity financings totaling approximately €15.7 million, through a combination of shares and warrants (including pre-funded warrants), subscribed by existing shareholders (including Heights Capital, Sofinnova, Invus, UPMC Enterprises and Alumni Capital) and new investors.

Based on its current cash position and projected cash flows, the Group’s available financial resources are insufficient to cover its operational requirements over the next twelve months.

Financial obligations

As of December 31, 2025, the Company’s financial debt of €22.9 million consists of:

• Tranche A of the EIB loan: €9.4 million (corresponding to the nominal amount plus accrued interest, repayable in a single bullet payment in February 2028, compared with a carrying amount of €7.0 million as of December 31, 2025);
• Convertible bonds in favor of Heights Capital: €6.3 million nominal amount (compared with a carrying amount of €5.5 million as of December 31, 2025), with quarterly amortization installments of €0.7 million, at the Group’s option in cash or shares, until December 2027;
• Conditional advances from Bpifrance: €7.2 million (corresponding to the nominal amount plus accrued interest, compared with a carrying amount of €5.0 million as of December 31, 2025, measured at amortized cost), with annual repayments starting in June 2026.

The financial debt does not include the refund liability (carrying amount of €5.0 million as of December 31, 2025) associated with potential rebates arising from the ATU (early access) program, which will be payable upon obtaining marketing authorization.

Business update

In December 2025, the ANSM granted Compassionate Use Authorization (Autorisation d’Accès Compassionnel, AAC) for the GS010/LUMEVOQ^® gene therapy in France. On March 9, 2026, the ANSM approved the first individual patient applications submitted under this AAC program. The first patients were treated on March 19, 2026, at the 15–20 National Hospital, with the first payments received end of March 2026. As of March 31, 2026, the Company’s available consolidated cash and cash equivalents amounted to €3.2 million.

Although the Group is unable to predict the precise timing of treatments and related payments under its various paid early access programs (in particular in France and Israel) over the coming year, management currently expects that aggregate revenues from these programs in 2026 should be sufficient to cover the Group’s operating expenses for that period, excluding costs associated with the new Phase III clinical trial including some of the manufacturing costs related to the study.

Financial outlook and mitigation plans

These early access revenues are not expected to be sufficient to fully fund the RECOVER Phase III clinical trial and the associated manufacturing costs. As a result, and in order to supplement its working capital and fund ongoing operating expenses, including preparation for and execution of the RECOVER Phase III clinical trial currently expected to start in the second quarter of 2027, the Company will need to obtain additional sources of financing (debt and/or equity) and/or expand international paid Early Access Programs beyond France and Israel and/or enter into out-licensing deal outside the USA and Europe, partnering or M&A transactions within the going concern assessment period and, in any case, before the end of 2026 in order to avoid to postpone the start of the Phase III study.

Going Concern Assessment

The Group’s assessment that the going concern basis of preparation remains appropriate is based on cash flow projections covering a period of at least twelve months from the date of authorization of these consolidated financial statements. These projections reflect the following key assumptions:

• The successful execution of the AAC program in France and other paid early access programs, generating aggregate revenues in 2026 sufficient to cover the Group’s operating costs for that period (excluding costs associated with the new Phase III clinical trial including some of the manufacturing costs related to this study);
• The availability, if required, of short‑term bridge financing prior to securing the structural funding required for the RECOVER Phase III clinical trial, in order to offset the fact that the Company does not know the precise timing of treatments and related payments;
• The Group’s ability to secure additional funds before the end of 2026, with the structural financing required for the RECOVER Phase III clinical trial expected to be obtained from one or more of the following sources: (i) a new equity financing, (ii) the potential drawdown of the €12 million non‑dilutive Tranche B under the existing EIB facility (subject to the satisfaction of milestone‑based conditions currently under discussion), (iii) expanding international paid Early Access Programs beyond France and Israel, and (iv) potential out‑licensing or partnering arrangements or M&A transaction;
• The Group’s ability to timely initiate manufacturing campaigns with, and provide adequate support to, its contract manufacturing organizations (CMOs) so as to rebuild and secure sufficient product inventories for treatments expected to be performed in 2027 and 2028.

While management believes that it will be able to raise additional funds and/or realize partnering or M&A opportunities, there can be no assurance that such transactions will be completed on a timely basis, in sufficient amounts or on acceptable terms. Failure to secure adequate funding could require the Group to significantly curtail or delay its operating plans, impair its ability to realize its assets and settle its liabilities in the normal course of business, or could ultimately lead to insolvency proceedings or the cessation of its operations in whole or in part.

These events and conditions, together with the uncertainties described above, indicate the existence of a material uncertainty that may cast significant doubt on the Company’s ability to continue as a going concern.

Financial Agenda

On April 7, 2026, GenSight Biologics will report its cash position as of March 31, 2026.

GenSight Biologics will hold its Annual General Meeting on May 19, 2026.

 Contact

Annual Consolidated Financial Statements (IFRS): Consolidated Balance Sheet

Annual Consolidated Financial Statements (IFRS): Consolidated income Statement

Annual Consolidated Financial Statements (IFRS): Consolidated Cash flow statement

 Annual Consolidated Financial Statements (IFRS): Change in Equity

 ⁽¹⁾ In 2025, 2,862,695 shares were issued following the exercise of convertible Bonds and the vesting of free share plans, and 143,201,440 new warrants and pre-funded warrants were subscribed but have not yet been exercised.

[1] Subject to the finalization of their audit procedures, the Auditors plan to issue an unqualified opinion on the annual and consolidated financial statements and to include a paragraph concerning the significant uncertainty related to the going concern detailed in the notes to the annual and consolidated financial statements.